Matinas BioPharma (MTNB) Q2 2026 earnings summary

Executive summary

• Entered into a Business Combination Agreement with GH Power Inc. and a Stock Purchase Agreement with Azurity Pharmaceuticals for the sale of Nanotechnologies, with the combined company to focus on GH Power's business post-closing.

• Net loss for the six months ended June 30, 2026 was $3.2M, a significant improvement from $6.9M in the prior year period.

• Substantial doubt exists about the ability to continue as a going concern due to insufficient cash to fund operations for the next twelve months.

Financial highlights

• Cash and cash equivalents at June 30, 2026 were $761K, down from $3.99M at year-end 2025.

• Stockholders' equity declined to $1.8M at June 30, 2026 from $4.8M at December 31, 2025.

• Net cash used in operating activities was $3.4M for the first half of 2026, compared to $4.0M in the prior year.

• No revenue was reported; all expenses were related to R&D and G&A.

Outlook and guidance

• The company does not expect to continue its historical clinical-stage activities after the business combination.

• If the business combination and asset sale are not completed, significant additional funding will be required, with no assurance of availability.